We are setting out the rationale for the choices made in our Country Awards starting with the winners from Bangladesh, Cambodia, Hong Kong and Hong Kong (Chinese financial institutions).

Speciality pharmaceutical company CF PharmTech is looking to raise at least $72 million in funding and has its sights set on an IPO in the near future.

Chinese industrial products supplier introduces the tech giant as a new investor as it continues its transformation from old-economy company into a fully fledged online distributor.

In a move to curb local government debt, regional governments will no longer guarantee the offshore bonds of local Chinese state firms.

Trade tensions and failed deals are preying on the minds of FinanceAsia’s readers as they ponder the M&A landscape for the year ahead.

Neither debt challenges nor international criticism dampened investor enthusiasm for Power Construction Corporation of China's 3-year and perpetual paper.

There are caveats though: the Sino-US trade war and the fact the renminbi is not yet fully convertible.

Besides Brexit concerns, limited investor demand and the small supply of companies are among the major factors that weigh on the plan to connect London and Shanghai.

Unfazed by critics over the legitimacy of its business model, Chinese healthcare crowdfunding site Shuidi raises $145 million from a star-studded list of investors.

The Korean conglomerate splashes out $1 billion on the world’s largest copper foil manufacturer, paying almost four times what KKR paid less than 18 months earlier.